文献速递甲状腺疾病

全国腹膜透析队列中甲状腺功能疾病与死亡率的关系

Thyroid Functional Disease and Mortality in a National Peritoneal Dialysis Cohort.
PubMed 文献 · J Clin Endocrinol Metab · 2016-08-15

该研究基于大型全国透析组织2007年1月至2011年12月接受腹膜透析且至少一次TSH检测的1484例患者,采用病例组合校正的时变Cox模型分析TSH与全因死亡的关系。结果显示时变TSH <0.1 mIU/L和≥5.0 mIU/L与较高死亡率相关,提示甲状腺功能亢进和减退在腹膜透析患者中带来短期风险。

要点

  • 腹膜透析患者基线时7%有甲状腺功能亢进,18%有甲状腺功能减退。
  • 时变TSH <0.1 mIU/L与全因死亡风险升高相关(校正HR 2.09,95%CI 1.08-4.06)。
  • 时变TSH ≥10.0 mIU/L与全因死亡风险升高相关(校正HR 3.11,95%CI 2.08-4.63)。

核心结论

  • 时变TSH <0.1 mIU/L和≥5.0 mIU/L与腹膜透析患者较高死亡率相关,提示甲状腺功能亢进和减退在该人群中带来短期风险。
  • 需要额外研究来确定甲状腺功能障碍与死亡率关联的机制,以及通过治疗使TSH正常化是否能改善该人群的死亡率。

研究设计与样本

  • 研究为来自大型全国透析组织的腹膜透析患者队列,纳入2007年1月至2011年12月5年间接受一次或多次TSH检测者,共1484例。
  • 甲状腺状态按TSH分为:明显甲状腺功能亢进(<0.1 mIU/L)、亚临床甲状腺功能亢进(0.1–<0.5 mIU/L)、正常低值(0.5–<3.0 mIU/L)、正常高值(3.0–<5.0 mIU/L)、亚临床甲状腺功能减退(5.0–<10.0 mIU/L)和明显甲状腺功能减退(≥10.0 mIU/L)。
  • 采用病例组合校正的时变Cox模型分析TSH与全因死亡率的关联,以评估短期甲状腺功能-死亡率关联并考虑甲状腺功能随时间的变化。

主要发现

  • 基线时1484例患者中7%有甲状腺功能亢进,18%有甲状腺功能减退。
  • 以TSH 0.5–<3.0 mIU/L为参照,时变TSH <0.1 mIU/L的校正HR为2.09(95%CI 1.08-4.06)。
  • 时变TSH 0.1–<0.5 mIU/L的校正HR为1.53(95%CI 0.87-2.70)。
  • 时变TSH 3.0–<5.0 mIU/L的校正HR为1.05(95%CI 0.75-1.46)。
  • 时变TSH 5.0–<10.0 mIU/L的校正HR为1.63(95%CI 1.11-2.40),≥10.0 mIU/L的校正HR为3.11(95%CI 2.08-4.63)。

局限性

  • 需要额外研究来确定甲状腺功能障碍与死亡率关联的机制,以及通过治疗使TSH正常化是否能改善该人群的死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT AND OBJECTIVE: End-stage renal disease patients have a higher risk of thyroid disease compared with those without kidney disease. Although thyroid dysfunction is associated with higher death risk in the general population and those undergoing hemodialysis, little is known about the effect of thyroid disease upon mortality in patients treated with peritoneal dialysis (PD). DESIGN, SETTING, PARTICIPANTS, AND MAIN OUTCOME: We examined the association of thyroid status, assessed by serum TSH, with all-cause mortality among PD patients from a large national dialysis organization who underwent one or more TSH measurements over 5 years (January 2007 to December 2011). Thyroid status was categorized as overt-hyperthyroid, subclinical-hyperthyroid, low-normal, high-normal, subclinical-hypothyroid, and overt-hypothyroid range (TSH < 0.1, 0.1–<0.5, 0.5–<3.0, 3.0–<5.0, 5.0–<10.0, and ≥10.0 mIU/L, respectively). We examined the association between TSH and mortality using case mix–adjusted time-dependent Cox models to assess short-term thyroid function–mortality associations and to account for changes in thyroid function over time. RESULTS: Among 1484 patients, 7 and 18% had hyperthyroidism and hypothyroidism, respectively, at baseline. We found that both lower and higher time-dependent TSH levels were associated with higher mortality (reference: TSH, 0.5-<3.0 mIU/L): adjusted hazard ratios (95% confidence intervals) 2.09 (1.08-4.06), 1.53 (0.87-2.70), 1.05 (0.75-1.46), 1.63 (1.11-2.40), and 3.11 (2.08-4.63) for TSH levels, <0.1, 0.1-<0.5, 0.5-<3.0, 3.0-<5.0, 5.0-<10.0, and ≥10.0 mIU/L, respectively. CONCLUSION: Time-dependent TSH levels < 0.1 mIU/L and ≥ 5.0 mIU/L were associated with higher mortality, suggesting hyper- and hypothyroidism carry short-term risk in PD patients. Additional studies are needed to determine mechanisms underlying the thyroid dysfunction-mortality association, and whether normalization of TSH with treatment ameliorates mortality in this population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rhee CM, Ravel VA, Streja E, et al. Thyroid Functional Disease and Mortality in a National Peritoneal Dialysis Cohort. J Clin Endocrinol Metab. 2016. PMID: 27525529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。